Lanean...
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. The promising antitumour activity of monoclonal antibodies targeting the immune-checkpoint proteins CTLA-4, PD-1, and PD-L1 led to regulatory approvals of these agents...
Gorde:
| Argitaratua izan da: | Nat Rev Clin Oncol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650537/ https://ncbi.nlm.nih.gov/pubmed/28653677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2017.88 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|